- Home
- PYPL vs TEVA Comparison
PYPL vs TEVA Comparison
Compare PYPL & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PYPL | TEVA |
|---|---|---|
| Founded | 1998 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.8B | 40.5B |
| IPO Year | 2015 | 1996 |
Fundamental Metrics
Financial Performance| Metric | PYPL | TEVA |
|---|---|---|
| Price | $54.46 | $38.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 42 | 8 |
| Target Price | ★ $56.92 | $46.29 |
| AVG Volume (30 Days) | ★ 9.6M | 4.4M |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | 35.59 | ★ 183.45 |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $33,172,000,000.00 | N/A |
| Revenue This Year | $4.76 | N/A |
| Revenue Next Year | $4.20 | $3.64 |
| P/E Ratio | $44.88 | ★ N/A |
| Revenue Growth | ★ 4.32 | N/A |
| 52 Week Low | $38.46 | $18.83 |
| 52 Week High | $79.22 | $40.79 |
Technical Indicators
Market Signals| Indicator | PYPL | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 50.79 | 53.30 |
| Support Level | $51.51 | $38.30 |
| Resistance Level | $55.55 | $40.79 |
| Average True Range (ATR) | 1.42 | 1.17 |
| MACD | 0.25 | -0.11 |
| Stochastic Oscillator | 70.81 | 24.30 |
Price Performance
Historical ComparisonAbout PYPL PayPal Holdings Inc.
PayPal was spun off from eBay in 2015 and provides electronic payment solutions to merchants and consumers, with a focus on online transactions. The company had 439 million active accounts at the end of 2025. The company also owns Venmo, a person-to-person payment platform.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.